Drugs in liver disease and during albumin dialysis -MARS.
Majcher-Peszynska
J
J
Department of Clinical Pharmacology, University of Rostock, Germany. jolanta.majcher-peszynska@medizin.uni-rostock.de
Peszynski
P
P
Müller
S C
SC
Klammt
S
S
Wacke
R
R
Mitzner
S
S
Stange
J
J
Mundkowski
R
R
Hehl
E M
EM
Schmidt
R
R
Drewelow
B
B
D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D001781:Blood Component Removal / Q000379:methods; D002442:Ceftazidime / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002443:Ceftriaxone / Q000493:pharmacokinetics* / Q000627:therapeutic use; D005112:Extracorporeal Circulation / Q000379:methods*; D006801:Humans; D008107:Liver Diseases / Q000188:drug therapy / Q000378:metabolism*; D008657:Metabolic Clearance Rate; D015242:Ofloxacin / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006435:Renal Dialysis / Q000379:methods*; D012709:Serum Albumin / Q000302:isolation & purification* / Q000378:metabolism*; D017334:Teicoplanin / Q000493:pharmacokinetics / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D012709:Serum Albumin; D017334:Teicoplanin; D002443:Ceftriaxone; D002442:Ceftazidime; D015242:Ofloxacin